Free Cash Flow

Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC (ADAP)

$4.53
-0.86 (-15.96%)
Year
A/P
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
Revenue 8.9814.2037.8359.511.121.642.393.495.097.43
Revenue (%)
Operating Cash Flow -18.06-48.17-54.31-104.39-112.51-35.65-52.03-75.94-110.82-161.73
Operating Cash Flow (%)
Capital Expenditure -9.84-12.79-25.01-4.71-3.07-1.79-2.62-3.82-5.57-8.14
Capital Expenditure (%)
Free Cash Flow -27.90-60.95-79.33-109.10-115.58-37.45-54.65-79.76-116.40-169.87

FCF Unlevered from cash flow statement